AbCellera Biologics Inc. (ABCL) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $821.24M; Additional Paid in Capital, Common StockUSD $206.00M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-3.15M; Retained Earnings (Accumulated Deficit)USD $-128.07M.
- 2026-03-31: Common Stock, Value, IssuedUSD $816.53M; Additional Paid in Capital, Common StockUSD $196.62M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-2.42M; Retained Earnings (Accumulated Deficit)USD $-72.65M.
- 2025-12-31: Common Stock, Value, IssuedUSD $802.34M; Additional Paid in Capital, Common StockUSD $198.28M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-4.23M; Retained Earnings (Accumulated Deficit)USD $-29.48M.
- 2025-09-30: Common Stock, Value, IssuedUSD $794.47M; Additional Paid in Capital, Common StockUSD $192.80M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-2.70M; Retained Earnings (Accumulated Deficit)USD $-20.54M.
AbCellera Biologics Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $821.24M | $206.00M | $-3.15M | $-128.07M | $896.02M | 3 month · $12.29M |
| 2026-03-31 | $816.53M | $196.62M | $-2.42M | $-72.65M | $938.08M | 3 month · $12.01M |
| 2025-12-31 | $802.34M | $198.28M | $-4.23M | $-29.48M | $966.90M | 12 month · $56.28M |
| 2025-09-30 | $794.47M | $192.80M | $-2.70M | $-20.54M | $964.04M | 3 month · $14.01M |
| 2025-06-30 | $791.67M | $181.48M | $-2.66M | $36.58M | $1.01B | 3 month · $14.41M |
| 2025-03-31 | $790.07M | $168.60M | $-7.00M | $71.31M | $1.02B | 3 month · $14.99M |
| 2024-12-31 | $777.17M | $166.36M | $-4.38M | $116.93M | $1.06B | 12 month · $67.58M |
| 2024-09-30 | $772.83M | $155.35M | $-1.23M | $151.14M | $1.08B | 3 month · $17.16M |
| 2024-06-30 | $769.97M | $140.83M | $-2.07M | $202.25M | $1.11B | 3 month · $17.78M |
| 2024-03-31 | $764.56M | $127.99M | $-1.82M | $239.18M | $1.13B | 3 month · $17.41M |
| 2023-12-31 | $753.20M | $121.05M | $-1.72M | $279.79M | $1.15B | 12 month · $64.18M |
| 2023-09-30 | $747.91M | $109.38M | $-1.46M | $326.94M | $1.18B | 3 month · $15.86M |
| 2023-06-30 | $744.76M | $96.42M | $-1.90M | $355.55M | $1.19B | 3 month · $16.40M |
| 2023-03-31 | $742.82M | $81.63M | $-2.02M | $386.07M | $1.21B | 3 month · $15.47M |
| 2022-12-31 | $734.37M | $74.12M | $-1.39M | $426.19M | $1.23B | 12 month · $49.48M |
| 2022-09-30 | $730.43M | $64.38M | $-717.00K | $456.08M | $1.25B | 3 month · $11.75M |
| 2022-06-30 | $726.83M | $56.00M | $576.00K | $429.45M | $1.21B | 3 month · $12.11M |
| 2022-03-31 | $725.75M | $44.73M | $787.00K | $436.24M | $1.21B | 3 month · $12.29M |
| 2021-12-31 | $722.43M | $35.36M | $280.00K | $267.67M | $1.03B | 12 month · $29.24M |
| 2021-09-30 | $718.09M | $26.95M | $644.00K | $207.72M | $953.40M | 3 month · $7.71M |
| 2021-06-30 | $714.76M | $21.67M | $2.15M | $229.10M | $967.68M | 3 month · $8.47M |
| 2021-03-31 | $711.14M | $14.56M | (m) | $231.42M | $957.12M | 3 month · $4.02M |
| 2020-12-31 | $710.39M | $5.92M | (m) | $114.20M | $830.51M | 12 month · $4.13M |
| 2020-09-30 | (m) | (m) | (m) | (m) | $89.26M | 3 month · $56.00K |
| 2020-06-30 | (m) | (m) | (m) | (m) | $90.89M | 3 month · $464.00K |
| 2020-03-31 | (m) | (m) | (m) | (m) | $83.69M | 3 month · $744.00K |
| 2019-12-31 | (m) | (m) | (m) | (m) | $10.25M | 12 month · $840.00K |
| 2018-12-31 | (m) | (m) | (m) | (m) | $11.61M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |